The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India):
Newer [...]
Below is an excerpt from the April 2009 Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."
The materials used in coronary stents must be flexible, supportive, capable of expansion, and biocompatible. Typically, foreign materials implanted into the human body results in trauma, inflammation, immune response and eventual healing and/or scarring. Materials that [...]
During the course of my review of recent premarket approvals (PMAs), I was once again startled (although I certainly shouldn’t be, having not too long ago done this same exercise on patent approvals) by the dominance of Medtronic. As an exercise (because exercise is important), I decided to just graph the January 2009 premarket approvals [...]
Contact:
